{"name": "Aerpio Therapeutics",
 "permalink": "aerpio-therapeutics",
 "crunchbase_url": "http://www.crunchbase.com/company/aerpio-therapeutics",
 "homepage_url": "http://www.aerpio.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "",
 "phone_number": "513.985.1920",
 "description": "",
 "created_at": "Fri Aug 31 02:31:49 UTC 2012",
 "updated_at": "Fri Aug 31 02:31:48 UTC 2012",
 "overview": "\u003Cp\u003EAerpio Therapeutics is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Aerpio was created in a spin-out transaction from Akebia Therapeutics to enable more rapid development of its exciting compounds. It is managed by the same successful team from Akebia, employing a similar outsourced approach to pharmaceutical development.\u003C/p\u003E\n\n\u003Cp\u003EAerpio\u0026#8217;s two lead programs include a Tie-2 activator for diabetic macular edema (DME) and vascular leak, and a Hypoxia-inducible Factor 1-\u03b1 (HIF1-\u03b1) stabilizer for wound healing and the treatment of inflammatory bowel disease. The lead compound for the Tie-2 program, AKB-9778, is currently completing its initial Phase 1 clinical trial, and the HIF1-\u03b1 stabilization program is progressing toward the clinic with support, in part, from the United States Department of Defense and National Institutes of Health.\u003C/p\u003E\n\n\u003Cp\u003EThe Aerpio team is composed of highly experienced individuals from all facets of pharmaceutical development. During the last 4 years, this team has successfully sharpened their skills at Akebia Therapeutics in the fast paced world of venture backed biopharmaceuticals.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[97,
       65],
      "assets/images/resized/0020/9041/209041v1-max-150x150.png"],
     [[97,
       65],
      "assets/images/resized/0020/9041/209041v1-max-250x250.png"],
     [[97,
       65],
      "assets/images/resized/0020/9041/209041v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "CEO",
    "person":
     {"first_name": "Joseph",
      "last_name": "H. Gardner",
      "permalink": "joseph-h-gardner",
      "image": null}},
   {"is_past": false,
    "title": "CSO",
    "person":
     {"first_name": "Kevin",
      "last_name": "Peters",
      "permalink": "kevin-peters",
      "image": null}},
   {"is_past": false,
    "title": "CMO",
    "person":
     {"first_name": "Robert",
      "last_name": "Shalwitz",
      "permalink": "robert-shalwitz",
      "image": null}},
   {"is_past": false,
    "title": "CFO",
    "person":
     {"first_name": "Ian",
      "last_name": "A.W. Howes",
      "permalink": "ian-a-w-howes",
      "image": null}},
   {"is_past": false,
    "title": "Member, Board of Directors",
    "person":
     {"first_name": "Duane",
      "last_name": "Nash",
      "permalink": "duane-nash",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$27M",
 "funding_rounds":
  [{"round_code": "a",
    "source_url": "http://www.finsmes.com/2012/08/aerpio-therapeutics-closes-27m-series-financing.html?utm_source=feedburner\u0026utm_medium=feed\u0026utm_campaign=Feed%3A+finsmes%2FcNHu+%28FinSMEs%29",
    "source_description": "Aerpio Therapeutics Closes $27M Series A Financing",
    "raised_amount": 27000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 8,
    "funded_day": 30,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Novartis Bioventures",
         "permalink": "novartis-bioventures",
         "image":
          {"available_sizes":
            [[[150,
               59],
              "assets/images/resized/0006/1683/61683v1-max-150x150.png"],
             [[250,
               98],
              "assets/images/resized/0006/1683/61683v1-max-250x250.png"],
             [[380,
               150],
              "assets/images/resized/0006/1683/61683v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Venture Investors",
         "permalink": "venture-investors",
         "image":
          {"available_sizes":
            [[[150,
               40],
              "assets/images/resized/0006/2067/62067v1-max-150x150.jpg"],
             [[217,
               58],
              "assets/images/resized/0006/2067/62067v1-max-250x250.jpg"],
             [[217,
               58],
              "assets/images/resized/0006/2067/62067v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Triathlon Medical Venture Partners",
         "permalink": "triathlon-medical-venture-partners",
         "image":
          {"available_sizes":
            [[[150,
               49],
              "assets/images/resized/0004/5663/45663v2-max-150x150.png"],
             [[200,
               66],
              "assets/images/resized/0004/5663/45663v2-max-250x250.png"],
             [[200,
               66],
              "assets/images/resized/0004/5663/45663v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Kearny Venture Partners",
         "permalink": "kearny-venture-partners",
         "image":
          {"available_sizes":
            [[[150,
               13],
              "assets/images/resized/0006/0719/60719v1-max-150x150.png"],
             [[250,
               22],
              "assets/images/resized/0006/0719/60719v1-max-250x250.png"],
             [[450,
               41],
              "assets/images/resized/0006/0719/60719v1-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Athenian Venture Partners",
         "permalink": "athenian-venture-partners",
         "image":
          {"available_sizes":
            [[[150,
               59],
              "assets/images/resized/0003/6232/36232v4-max-150x150.jpg"],
             [[250,
               98],
              "assets/images/resized/0003/6232/36232v4-max-250x250.jpg"],
             [[450,
               177],
              "assets/images/resized/0003/6232/36232v4-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "AgeChem Venture Fund",
         "permalink": "agechem-venture-fund",
         "image":
          {"available_sizes":
            [[[150,
               27],
              "assets/images/resized/0006/8086/68086v1-max-150x150.jpg"],
             [[250,
               45],
              "assets/images/resized/0006/8086/68086v1-max-250x250.jpg"],
             [[343,
               63],
              "assets/images/resized/0006/8086/68086v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "9987 Carver Road",
    "address2": "Suite 420",
    "zip_code": "45242",
    "city": "Cincinnati",
    "state_code": "OH",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}